ICU Medical, Inc. $ICUI Stock: Reinhart Partners LLC. Boosts Stake

Reinhart Partners LLC. increased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 2.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 322,095 shares of the medical instruments supplier’s stock after buying an additional 7,327 shares during the period. Reinhart Partners LLC. owned 1.29% of ICU Medical worth $51,699,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ICUI. Versant Capital Management Inc increased its stake in shares of ICU Medical by 26.2% during the 3rd quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 65 shares during the last quarter. Squarepoint Ops LLC bought a new position in ICU Medical during the second quarter worth about $3,744,000. Allworth Financial LP grew its holdings in ICU Medical by 155.1% during the second quarter. Allworth Financial LP now owns 176 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 107 shares during the period. Arizona State Retirement System increased its position in ICU Medical by 1.7% during the second quarter. Arizona State Retirement System now owns 6,551 shares of the medical instruments supplier’s stock worth $960,000 after buying an additional 109 shares during the last quarter. Finally, Nykredit A S acquired a new position in ICU Medical during the second quarter worth approximately $135,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Activity at ICU Medical

In related news, VP Virginia Sanzone sold 4,856 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the transaction, the vice president directly owned 14,604 shares of the company’s stock, valued at approximately $2,463,548.76. This trade represents a 24.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Christian Voigtlander sold 8,929 shares of ICU Medical stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the sale, the chief operating officer owned 37,377 shares of the company’s stock, valued at $6,837,374.61. This trade represents a 19.28% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 21,830 shares of company stock valued at $3,905,003. 2.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. KeyCorp raised their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Raymond James Financial restated a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a research note on Friday, August 7th. Needham & Company LLC raised their price target on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $192.80.

ICU Medical Price Performance

ICU Medical stock opened at $160.32 on Friday. The company has a market capitalization of $4.01 billion, a price-to-earnings ratio of 135.86, a PEG ratio of 1.98 and a beta of 0.86. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. ICU Medical, Inc. has a 12 month low of $112.50 and a 12 month high of $192.85. The stock’s 50 day moving average is $168.41 and its 200-day moving average is $148.25.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The business had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. During the same period last year, the firm posted $2.10 EPS. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts expect that ICU Medical, Inc. will post 7.22 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and critical care. Its products support the delivery of medications, fluids, and nutrition while helping healthcare providers reduce the risk of complications associated with intravenous treatment.

The company’s product portfolio includes infusion pumps and related administration sets, needle-free connectors, vascular access devices, intravenous systems, and other products used in hospitals and alternate-care settings.